U.S. In-Vitro Diagnostic Substances Market. Analysis And Forecast to 2025

IndexBox has just published a new report "U.S. In-Vitro Diagnostic Substances Market. Analysis And Forecast to 2025" ( http://www.indexbox.co.uk/store/us-in-vitro-diagnostic-substances-market-analysis-and-forecast-to-2020?utm_source=opr ).

The report provides on an in-depth survey of the U.S. in-vitro diagnostic substance market. It depicts the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. In addition, the report contains insightful information about the industry, including industry life cycle, business locations, productivity, employment and many other crucial aspects. The Company Profiles section contains existing data on the leading players in the industry.

Countries coverage: the U.S.

Product coverage:
In-vitro diagnostic substances

Abstract:
In 2015, the value of in-vitro diagnostic substance production in the U.S. amounted to $11.7B, surging by +4.8% against the previous year level. Overall, the U.S. in-vitro diagnostic substance output pursued a significant growth from 2007 to 2015. The total output figures increased at an average annual rate of +3.4%. The trend pattern, however, indicated some noticable fluctuations throughout the analyzed period. The growth pace was the most rapid in 2010, when the output figure increased by +25% from the previous year level. Over the period under review, the total value of in-vitro diagnostic substance shipments in the United States attained its maximum level of $12.0B in 2013. Afterwards, the growth in terms of the in-vitro diagnostic substance production failed to regain its strength through to 2015.

Companies mentioned:
Abbott Diabetes Care,
Orasure Technologies,
Amag Pharmaceuticals,
Streck, Diasorin Inc.,
Diadexus,
Rapid Pathogen Screening,
Maine Biotechnology Services,
Saladax Biomedical,
Corgenix Medical Corporation,
George King Bio-Medical,
Princeton Biomeditech Corp,
Banyan Biomarkers,
Anatech,
Dxna LLC,
CD Diagnostics,
Akers Biosciences,
Helica Biosystems,
Green Mountain Antibodies,
Biospacific, Innominata,
Phase 2 Discovery,
Immuno Concepts,
Hepatochem,
Lifecare Medical International,
Horizon Diagnostic,
Immucor Gti Diagnostics,
Werfen USA,
Ivd Intermediate Holdings B Inc.,
Opko Diagnostics,
Horizon Diagnostic Inc,
Immucor Gti Diagnostics,
Werfen USA,
Ivd Intermediate Holdings B Inc.,
Opko Diagnostics

Data coverage:
• In-vitro diagnostic substance market size;
• In-vitro diagnostic substance production, value of shipments;
• Key market players and their profiles;
• Exports, imports and trade balance;
• Import and export prices;
• Forecast of the market dynamics in the medium term;
• Key industry statistics;
• Life cycle of the in-vitro diagnostic substance industry;
• Number of establishments and their locations;
• Employment data;
• In-vitro diagnostic substance industry productivity.

Reasons to buy this report:
• Take advantage of the latest data;
• Find deeper insights into current market developments;
• Discover vital success factors affecting the market.

Source: http://www.indexbox.co.uk/store/us-in-vitro-diagnostic-substances-market-analysis-and-forecast-to-2020?utm_source=opr

IndexBox is a leading market research publisher in the world. You can find more than 25,000 research reports in our web store, which cover global industries and regional markets. All the worldwide marketing data you need is at your fingertips.

Company Name: IndexBox
Contact Person: Kirill Bezverhi
Email: kirill.bezverhi@indexbox.co.uk
Phone: +44 20 3239 3063
Adress: United Kingdom, 44 Main Street, Douglas, South Lanarkshire, Scotland, ML11 0QW

This release was published on openPR.